Chamberlain NR 565 Final Exam 3– Advanced Pharmacology Actual Questions
and Answers (PDF).
Review Rationales: Even for questions you get right, read the rationale to solidify
your understanding of the concept.
Focus on Weak Areas: Use the topic headings (e.g., Pharmacokinetics, Endocrine)
to identify where you need more study.
Answer Key
(For quick checking. Detailed rationales follow in the main list below).
1. B | 2. B | 3. C | 4. C | 5. C | 6. B | 7. B | 8. B | 9. C | 10. B |
11. B | 12. B | 13. C | 14. A | 15. B | 16. C | 17. A | 18. B | 19. B | 20. D |
21. C | 22. B | 23. C | 24. D | 25. C | 26. A | 27. C | 28. D | 29. B | 30. A |
31. A | 32. C | 33. C | 34. B | 35. B | 36. D | 37. B | 38. C | 39. B | 40. C |
41. B | 42. B | 43. A | 44. A | 45. A | 46. D | 47. A | 48. B | 49. A | 50. B |
Main Question Bank
Topic 1: Pharmacokinetics & Pharmacodynamics (Qs 1-20)
,1. A drug that is a weak base with a pKa of 8.5 will be best absorbed in which
environment?
A. Stomach (pH 1.5 - 2.0)
B. Small intestine (pH 6.0 - 7.5)
C. Blood (pH 7.35 - 7.45)
D. Urine (pH 5.0 - 8.0)
Answer: B. Small intestine (pH 6.0 - 7.5)
Rationale: Weak bases are non-ionized (lipid-soluble) and well absorbed in
alkaline environments. Using the Henderson-Hasselbalch equation, a base is non-
ionized when the pH is higher than the pKa. The small intestine has a higher pH
(6-7.5) compared to the stomach, making it the primary site of absorption for
weak bases .
2. A patient is taking two highly protein-bound drugs (95% and 97%). What is the
most likely pharmacokinetic outcome?
A. Decreased drug half-life
B. Drug displacement and increased free drug concentration
C. Decreased risk of toxicity
D. Enhanced renal excretion
,Answer: B. Drug displacement and increased free drug concentration
Rationale: Highly protein-bound drugs compete for binding sites on albumin. If
one drug is displaced, the free (unbound) concentration of the other drug
increases suddenly, potentially leading to toxicity until the excess free drug is
metabolized and eliminated .
3. A patient with hepatic cirrhosis is likely to have significantly reduced
metabolism of drugs primarily processed by the liver. This affects which
pharmacokinetic phase?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Answer: C. Metabolism
Rationale: The liver is the primary site of drug metabolism (biotransformation).
Cirrhosis reduces hepatic blood flow and enzyme activity (CYP450 system),
leading to decreased clearance and prolonged half-life of many drugs like
benzodiazepines and opioids .
, 4. A medication has a half-life of 6 hours. Approximately how long will it take to
reach steady state?
A. 12 hours
B. 18 hours
C. 30 hours
D. 48 hours
Answer: C. 30 hours
Rationale: Steady state is reached after approximately 4-5 half-lives. For a drug
with a 6-hour half-life: 5 × 6 = 30 hours. This is when drug input equals drug
output .
5. A medication with a narrow therapeutic index (NTI) requires careful monitoring
because:
A. It has a wide margin of safety
B. It is only available intravenously
C. Small changes in dose can lead to toxicity or inefficacy
D. It has no reported side effects
Answer: C. Small changes in dose can lead to toxicity or inefficacy
and Answers (PDF).
Review Rationales: Even for questions you get right, read the rationale to solidify
your understanding of the concept.
Focus on Weak Areas: Use the topic headings (e.g., Pharmacokinetics, Endocrine)
to identify where you need more study.
Answer Key
(For quick checking. Detailed rationales follow in the main list below).
1. B | 2. B | 3. C | 4. C | 5. C | 6. B | 7. B | 8. B | 9. C | 10. B |
11. B | 12. B | 13. C | 14. A | 15. B | 16. C | 17. A | 18. B | 19. B | 20. D |
21. C | 22. B | 23. C | 24. D | 25. C | 26. A | 27. C | 28. D | 29. B | 30. A |
31. A | 32. C | 33. C | 34. B | 35. B | 36. D | 37. B | 38. C | 39. B | 40. C |
41. B | 42. B | 43. A | 44. A | 45. A | 46. D | 47. A | 48. B | 49. A | 50. B |
Main Question Bank
Topic 1: Pharmacokinetics & Pharmacodynamics (Qs 1-20)
,1. A drug that is a weak base with a pKa of 8.5 will be best absorbed in which
environment?
A. Stomach (pH 1.5 - 2.0)
B. Small intestine (pH 6.0 - 7.5)
C. Blood (pH 7.35 - 7.45)
D. Urine (pH 5.0 - 8.0)
Answer: B. Small intestine (pH 6.0 - 7.5)
Rationale: Weak bases are non-ionized (lipid-soluble) and well absorbed in
alkaline environments. Using the Henderson-Hasselbalch equation, a base is non-
ionized when the pH is higher than the pKa. The small intestine has a higher pH
(6-7.5) compared to the stomach, making it the primary site of absorption for
weak bases .
2. A patient is taking two highly protein-bound drugs (95% and 97%). What is the
most likely pharmacokinetic outcome?
A. Decreased drug half-life
B. Drug displacement and increased free drug concentration
C. Decreased risk of toxicity
D. Enhanced renal excretion
,Answer: B. Drug displacement and increased free drug concentration
Rationale: Highly protein-bound drugs compete for binding sites on albumin. If
one drug is displaced, the free (unbound) concentration of the other drug
increases suddenly, potentially leading to toxicity until the excess free drug is
metabolized and eliminated .
3. A patient with hepatic cirrhosis is likely to have significantly reduced
metabolism of drugs primarily processed by the liver. This affects which
pharmacokinetic phase?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Answer: C. Metabolism
Rationale: The liver is the primary site of drug metabolism (biotransformation).
Cirrhosis reduces hepatic blood flow and enzyme activity (CYP450 system),
leading to decreased clearance and prolonged half-life of many drugs like
benzodiazepines and opioids .
, 4. A medication has a half-life of 6 hours. Approximately how long will it take to
reach steady state?
A. 12 hours
B. 18 hours
C. 30 hours
D. 48 hours
Answer: C. 30 hours
Rationale: Steady state is reached after approximately 4-5 half-lives. For a drug
with a 6-hour half-life: 5 × 6 = 30 hours. This is when drug input equals drug
output .
5. A medication with a narrow therapeutic index (NTI) requires careful monitoring
because:
A. It has a wide margin of safety
B. It is only available intravenously
C. Small changes in dose can lead to toxicity or inefficacy
D. It has no reported side effects
Answer: C. Small changes in dose can lead to toxicity or inefficacy
